FIRST AMENDMENT TO COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • August 1st, 2018 • Exelixis, Inc. • Services-commercial physical & biological research
This FIRST AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT (the “Amendment”) is entered into as of March 22, 2018 (the “Amendment Effective Date”) by and between Exelixis, Inc., a Delaware company having an address at 210 East Grand Avenue, South San Francisco, CA 94080, USA (“Exelixis”) and Takeda Pharmaceutical Company Limited, a Japanese corporation with principal offices located at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, JAPAN (“Collaborator”). Exelixis and Collaborator may be referred to herein individually as a “Party” or collectively as the “Parties”.
SECOND AMENDMENT TO LEASE AGREEMENTLease Agreement • August 1st, 2018 • Exelixis, Inc. • Services-commercial physical & biological research
THIS SECOND AMENDMENT TO LEASE AGREEMENT (this “Second Amendment”) effective as of June 13, 2018 (the “Second Amendment Effective Date”), is made and entered into by and between ASCENTRIS 105, LLC, a Colorado limited liability company (“Landlord”), and EXELIXIS, INC., a Delaware corporation (“Tenant”).
